Considering that SMYD2 regulates p53 activity, our results demonstrate the importance of the SMYD2/miRNA-EMT/MDR pathway in drug resistance and the development of ccRCC. This evidence concerns the gene SMYD2 and nonpapillary renal cell carcinoma.